CIK 0001582313 · Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- EIN
- 980661854
- Phone
- (604) 484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-01 | Svoronos Dawn Director | Option exercise · Restricted Share Units | −2,645 | 0 | ||
| 2026-05-12 | GANNON STEVEN Director | Option exercise | +3,500 | $7.38 | $26K | 10,641 |
| 2026-05-12 | GANNON STEVEN Director | Option exercise · Stock Option (Right to Buy) | −3,500 | 0 | ||
| 2026-03-13 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Sale 10b5-1 | −1,410 | $55.23 | $78K | 7,069 |
| 2026-03-13 | DiFabio Andrea Chief Legal Officer | Sale 10b5-1 | −1,342 | $55.23 | $74K | 7,301 |
| 2026-03-13 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −7,308 | $55.23 | $404K | 19,923 |
| 2026-03-12 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Option exercise 10b5-1 | +3,750 | 8,479 | ||
| 2026-03-12 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Option exercise · Restricted Share Units 10b5-1 | −3,750 | 11,250 | ||
| 2026-03-12 | DiFabio Andrea Chief Legal Officer | Option exercise 10b5-1 | +3,750 | 8,643 | ||
| 2026-03-12 | DiFabio Andrea Chief Legal Officer | Option exercise · Restricted Share Units 10b5-1 | −3,750 | 11,250 | ||
| 2026-03-12 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 | +12,500 | 27,231 | ||
| 2026-03-12 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Restricted Share Units 10b5-1 | −12,500 | 37,500 | ||
| 2026-03-10 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Sale 10b5-1 | −2,771 | $60.11 | $167K | 4,729 |
| 2026-03-10 | DiFabio Andrea Chief Legal Officer | Sale 10b5-1 | −2,607 | $60.11 | $157K | 4,893 |
| 2026-03-10 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −11,269 | $60.11 | $677K | 14,731 |
| 2026-03-09 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Option exercise 10b5-1 | +7,500 | 7,500 | ||
| 2026-03-09 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Grant or award · Performance Share Units 10b5-1 | +7,500 | 7,500 | ||
| 2026-03-09 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Option exercise · Performance Share Units 10b5-1 | −7,500 | 0 | ||
| 2026-03-09 | DiFabio Andrea Chief Legal Officer | Option exercise 10b5-1 | +7,500 | 7,500 | ||
| 2026-03-09 | DiFabio Andrea Chief Legal Officer | Grant or award · Performance Share Units 10b5-1 | +7,500 | 7,500 |
Page 3 of 16 · 308 trades